Madrigal Pharmaceuticals Inc (MDGL) reported disappointing financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) stood at $-4.96, significantly missing Wall Street's consensus estimate of $-2.12 by $2.84. Revenue matched expectations at $0.3 billion, but the overall performance fell short of analyst estimates.
The company, headquartered in West Conshohocken, Pennsylvania, develops innovative therapeutic candidates for cardiovascular, metabolic, and liver diseases. Its primary product, Rezdiffra (resmetirom), is designed to treat nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring and has received FDA approval for use in patients with moderate to advanced fibrosis.
Madrigal Pharmaceuticals will host an earnings conference call to discuss these results and provide further insights into its business performance. Investors are encouraged to review the full earnings release and listen to management commentary for a comprehensive understanding of the quarter's performance and future outlook.
With a market capitalization of $11.17 billion and an EPS of -12.85 for the trailing twelve months, Madrigal continues to navigate a challenging landscape. Upcoming earnings are scheduled for August 2, 2026, with an estimated EPS of 0.7825 and revenue of $0.4 billion, followed by another report on April 28, 2026, with an estimated EPS of -1.3107 and revenue of $0.3 billion.